| 8575214 |
MGlu 2/3 agonists |
Stephen R. Baker, Christopher David Beadle, James Allen Monn, Lourdes Prieto |
2013-11-05 |
$105,572,000 |
| 8202873 |
2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists |
Valentina Badescu, Anne Marie Camp, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher +6 more |
2012-06-19 |
$208,205,000 |
| 7619096 |
3-Aminopyrrolidines as inhibitors of monoamine uptake |
Christopher David Beadle, Manuel Javier Cases-Thomas, Peter Thaddeus Gallagher, John Joseph Masters, Graham H. Timms +4 more |
2009-11-17 |
$86,653,000 |
| 7615648 |
Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake |
John Richard Harris, Peter Thaddeus Gallagher, Maria Ann Whatton |
2009-11-10 |
$126,664,000 |
| 7521462 |
4-Amino-piperidine derivatives as monoamine uptake inhibitors |
Serge Louis Boulet, John Fairhurst, Peter Thaddeus Gallagher, Anette Johansson, Maria Ann Whatton +1 more |
2009-04-21 |
$246,974,000 |
| 7488728 |
Pyridinylmorpholine derivatives |
Peter Thaddeus Gallagher |
2009-02-10 |
$289,522,000 |
| 7432280 |
3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake |
Christopher David Beadle, Manuel Javier Cases-Thomas, Peter Thaddeus Gallagher, John Joseph Masters, Graham H. Timms +4 more |
2008-10-07 |
$238,965,000 |
| 7384941 |
2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
Magnus Wilhelm Walter, Peter Thaddeus Gallagher, Helen Louise Haughton, Helene Rudyk |
2008-06-10 |
$65,113,000 |
| 7294623 |
Benzyl morpholine derivatives |
Peter Thaddeus Gallagher, Helen Louise Haughton |
2007-11-13 |
$94,713,000 |
| 6482824 |
Use of n-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives as selective mglur1 antagonists |
John Richard Harris, Ann E. Kingston |
2002-11-19 |
$499,026,000 |
| 6054448 |
2-amino-2-(3-substituted cyclobutyl) acetic acid derivatives |
John Richard Harris |
2000-04-25 |
$765,667,000 |
| 5891899 |
Pharmaceutical xanthene compounds |
John Richard Harris |
1999-04-06 |
$193,171,000 |
| 5863947 |
Phenylglycine derivatives useful for treating disorders of the central nervous system |
Stephen R. Baker, John Goldsworthy, John Richard Harris |
1999-01-26 |
$411,146,000 |
| 5580900 |
Macrocyclic compounds |
John Richard Harris |
1996-12-03 |
$3,252,000 |
| 5574158 |
Compounds |
John Richard Harris |
1996-11-12 |
$3,205,000 |
| 5428065 |
1,3-benzenedimethanamines useful as central nervous system active agents |
Graham H. Timms |
1995-06-27 |
$3,042,000 |
| 5258378 |
Pyrroloazepine compounds useful as dopaminergic agents |
Graham H. Timms, David E. Tupper |
1993-11-02 |
$3,375,000 |
| 5028602 |
Pharmaceutical compounds |
David E. Tupper |
1991-07-02 |
$1,361,000 |
| 4904653 |
Thieno[2,3-O]azepine compounds and CNS affecting use thereof |
David E. Tupper |
1990-02-27 |
$474,000 |
| 4471129 |
6-Substituted pyranone compounds and their use as pharmaceuticals |
William J. Ross, Alec Todd |
1984-09-11 |
$653,000 |
| 4448787 |
6-Substituted pyranone compounds and their use as pharmaceuticals |
William J. Ross, Alec Todd |
1984-05-15 |
$448,000 |
| 4364956 |
5-Substituted pyranone compounds and their use as pharmaceuticals to treat an immediate hypersensitivity condition |
William J. Ross, Alec Todd |
1982-12-21 |
$301,000 |
| 4304728 |
6-Substituted pyranone compounds and their use as pharmaceuticals |
William J. Ross, Alec Todd |
1981-12-08 |
$323,000 |
